CID_16020046_DataSheet_MedChemExpress

合集下载

Gelucire-14-44-SDS-MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Nov.-23-2018Print Date:Nov.-23-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gelucire 14/44Catalog No. :HY-Y1892CAS No. :121548-04-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:N/AMolecular Weight:N/ACAS No. :121548-04-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Pure form-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Oil)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

超高效液相色谱-串联质谱法测定化妆品中21种抗组胺类药物

m f P鞴骟-圯莩分冊________________PTCACPART B: CHEM. ANAL.)专题报道DOI ： 10.11973/lhjy-hx2()2105015超高效液相色谱-串联质谱法测定化妆品中21种抗组胺类药物吕稳1’2,李红英“2,李丽霞“2,丁晓萍“2(1.湖北省药品监督检验研究院，武汉430075; 2.湖北省药品质量检测与控制工程技术研究中心，武汉430075)摘要：建立了超高效液相色谱-串联质谱法（UHPLC-MS/M S)测定化妆品中21种抗组胺类药物的方法。

样品用甲醇提取后，采用Waters AC'QUITY UPLC BEH-C18色谱柱分离21个组分，以曱醇-含0.1 mol .L1甲酸铵的0.1%(体积分数）甲酸溶液为流动相进行梯度洗脱，在电喷雾离子源正离子（E S F〉模式下电离，多反应监测（MRM)模式下检测。

结果显示：21种抗组胺类药物的质量浓度均在5〜250 pg •I，1内与其对应的峰面积呈线性关系，检出限（3S/N)为0.1〜0.5 /xg .L、在3种基质中的加标回收率为80.2%〜110%，测定值的相对标准偏差（h=6)为1.5%〜7.9%。

方法用于50批面膜样品的分析，均未检出21种抗组胺类药物。

关键词：超高效液相色谱-串联质谱法；抗组胺类药物；化妆品中图分类号：0657.63 文献标志码：A 文章编号：1001-4020(2021)05-0470-06化妆品由于基质复杂、辅料繁多，又与人体皮肤直接接触，常引起过敏反应，其主要过敏原有防腐剂、芳香混合物、重金属、激素、中药提取物等[12]。

为减轻过敏反应，化妆品中有添加抗过敏药物的风险。

组胺是引起人体皮肤过敏反应的主要化学物质，因此抗组胺类药物是目前主要使用的抗敏剂。

然而，长期使用抗组胺类药物会引起多种不良反应，如嗜睡、变应性接触性皮炎、心脏毒性等，还会让皮肤对其产生依赖性，停止使用后过敏症状加重，可能引起毛细管扩张、色素沉着、内分泌紊乱等不良反应[35]。

Febuxostat_DataSheet_MedChemExpress

Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:Febuxostat(TEI 6720;TMX 67 ) is selective xanthine oxidase inhibitor with Ki of 0.6 nM.IC50 value: 0.6 nM (Ki) [1]Target: xanthine oxidasein vitro: Febuxostat displays potent mixed–type inhibition of the activity of purified bovine milk xanthine oxidase, with Ki and Ki' values of 0.6 nM and 3.1 nM respectively, indicating inhibition of both the oxidized and reduced forms of xanthine oxidase [1].in vivo: Febuxostat (5–6 mg/kg/day) combined with fructose significantly lowers blood pressure, UA, triglycerides, and insulin in rats compared with fructose alone. Febuxostat (5–6 mg/kg/day) combined with fructose also reduces glomerular pressure, renal vasoconstriction, and afferent arteriolar area in rats compared with fructose alone [2]. Febuxostat prevents hyperuricemia in 5/6nephrectomy (5/6 Nx)+oxonic acid (OA)+Febuxostat(Fx) rats and ameliorates proteinuria, preserves renal function and prevents glomerular hypertension in both 5/6 nephrectomy (5/6 Nx)+vehicle (V)+Febuxostat(Fx) and 5/6 nephrectomy (5/6 Nx)+oxonic acid (OA)+Febuxostat(Fx) groups [3]. Febuxostat (5 mg/kg/d by gavage for 8 days) treatment after transverse aortic constriction (TAC)attenuates the TAC–induced left ventricular (LV) hypertrophy and dysfunction. Febuxostat blunts the TAC–induced increases innitrotyrosine (indicating reduced myocardial oxidative stress), p–Erk(Thr202/Tyr204), and p–mTOR(Ser2488), with no effect on total Erk or total mTOR [4].References:[1]. Takano Y, et al. Selectivity of febuxostat, a novel non–purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci, 2005, 76(16), 1835–1847.[2]. Sánchez–Lozada LG, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose–induced metabolic syndrome. Am J Physiol Renal Physiol, 2008, 294(4), F710–F718.[3]. Sánchez–Lozada LG, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol, 2008, 108(4), p69–p78.[4]. Xu X, et al. Xanthine oxidase inhibition with febuxostat attenuates systolic overload–induced left ventricular hypertrophy and dysfunction in mice. Card Fail, 2008, 14(9), 746–753.Product Name:Febuxostat Cat. No.:HY-14268CAS No.:144060-53-7Molecular Formula:C 16H 16N 2O 3S Molecular Weight:316.37Target:Xanthine Oxidase Pathway:Metabolic Enzyme/Protease Solubility:10 mM in DMSOCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

高效液相色谱法测定木瓜片中欧前胡素的含量

高效液相色谱法测定木瓜片中欧前胡素的含量作者：叶挺祥刘征辉赵洪芝刘新元李春程奕罗国安【摘要】目的建立木瓜片中欧前胡素的高效液相色谱（HPLC）含量测定方法。

方法色谱柱为Agilent Eclipse XDB C18柱（4.6 mm×250 mm， 5 μm）；流动相为甲醇-水（59∶41）；流速1.0 ml/min；波长248 nm，柱温30℃。

结果欧前胡素线性范围为 5.64～56.4 mg（r=0.999 4）；平均回收率分别为97.8% （RSD为1.65%）。

结论所建定量方法专属性强，重复性好，可为木瓜片的质量控制方法。

【关键词】木瓜片; 欧前胡素; 高效液相色谱法; 白芷Abstract：ObjectiveTo establish the quality standard for Mugua Tablets. MethodsThe content of Imperatorin was determined by HPLC. The chromatographic column was an Agilent Eclipse XDB C18 (4.6 mm×250 mm，5 mm)， the mobile phase was methanol-water (59∶41)， the detection wavelength was 294 nm， the flow rate was 1.0 ml/min， and the column temperature was 30℃. ResultsThe linear ranges of imperatorin were with in the range of 5.54 to 56.4mg (r=0.999 4). The average recovery was 97.8% (RSD was 1.65 %) . ConclusionThe HPLC method is exclusive，reproducible and suitable for the quality control of Mugua Tablets.Key words：Mugua Tablets; Imperatorin; HPLC; Radix Angelicae Dahuricae木瓜片收载于部颁药品标准(WS3-B-1890-95)，由木瓜、当归、川芎、白芷等12味中药材组成，主要用于风寒湿痹，四肢麻木，周身疼痛，腰膝无力，步履艰难。

Alda-1_DataSheet_MedChemExpress

Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:Alda–1 is a potent ALDH2 agonist, which significantly improves ALDH2 activity.In Vivo: Alda–1 treatment results in a significant decrease of 4–HNE–protein content in the plasma of apoE -/- mice. Alda–1administration leads to a slight increase in gene expression related to neurogenesis (Nog ), mitochondrial biogenesis (CYTB , ND1),and apoptosis (Bax , Gsk3b ) in the Hp of apoE -/- mice. Alda–1 administration leads to 2 and 10 differentially expressed proteins in theFCx and Hp of apoE -/- mice, respectively [1]. Alda–1 (1.5 mg/kg, b.w., i.p.) administration significantly increases the climbing time,tends to reduce the immobility time and increases the swimming time of the prenatally stressed rats in the forced swim test.Moreover, treatment of prenatally stressed rats with Alda–1 significantly increases number of entries into the open arms of the maze and the time spent therein, as assessed by elevated plus–maze test [2]. Alda–1 (8.5 mg/kg, i.p.) with glucose significantly lowers 4–HNE and FJB–positive cells in the cerebral cortex of Alda–1–treated rats than in DMSO–treated rats 24 h after glucose administration [3]. Alda–1 (10 mg/kg per day) treatment prevents aldehydic overload, mitochondrial dysfunction and improves ventricular function in post–MI cardiomyopathy rats [4].PROTOCOL (Extracted from published papers and Only for reference)Cell Assay:[2]Spleen cells (4×106 cells/mL) are stimulated by optimal concentrations of concanavalin A (Con A; 2.5μg/mL and 0.6 μg/mL) and lipopolysaccharide (LPS, 5 μg/mL) and are incubated in 96–well plates at final volume of 0.2mL for 72 h. Cell proliferation is determined by adding 0.5 μCi of [3H]–thymidine per well at 16 h before the end of the incubation.The cultures are harvested with an automatic cell harvester, and [3H] thymidine incorporation is assessed using a liquid scintillationcounter.Animal Administration: Alda–1 is dissolved in 1 mL/kg b.w. DMSO/water 50/50.[2]After behavioral verification at three months of age,the animals are divided into the following four groups: control, control + Alda–1, prenatally stressed and prenatally stressed + Alda–1(6 animals per group). Alda–1 injections are given intraperitoneally (i.p.) once daily at a dose of 1.5 mg/kg b.w. (dissolved in 1 mL/kg b.w. DMSO/water 50/50) for 14 days. At the same time, the control and prenatally stressed rats receive 1 mL/kg b.w. DMSO/water 50/50. The injections of Alda–1 and vehicle are given between 10 a.m and 11 a.m. In the last five days of Alda–1 treatment the behavioral parameters in the elevated plus maze test and then in the forced swim test are measured.References:[1]. Stachowicz A, et al. Proteomic Analysis of Mitochondria–Enriched Fraction Isolated from the Frontal Cortex and Hippocampus of Apolipoprotein E Knockout Mice Treated with Alda–1, an Activator of Mitochondrial Aldehyde Dehydrogenase (ALDH2). Int J Mol Sci.[2]. Stachowicz A, et al. The impact of mitochondrial aldehyde dehydrogenase (ALDH2) activation by Alda–1 on the behavioral and biochemical disturbances in animal model of depression. Brain Behav Immun. 2016 Jan;51:144–53.Product Name:Alda–1Cat. No.:HY-18936CAS No.:349438-38-6Molecular Formula:C 15H 11Cl 2NO 3Molecular Weight:324.16Target:Aldehyde Dehydrogenase (ALDH)Pathway:Metabolic Enzyme/Protease Solubility:DMSO: ≥ 51 mg/mL[3]. Ikeda T, et al. Effects of Alda–1, an Aldehyde Dehydrogenase–2 Agonist, on Hypoglycemic Neuronal Death. PLoS One. 2015 Jun 17;10(6):e0128844.[4]. Gomes KM, et al. Aldehydic load and aldehyde dehydrogenase 2 profile during the progression of post–myocardial infarction cardiomyopathy: benefits of Alda–1. Int J Cardiol. 2015 Jan 20;179:129–138.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

CID-16020046-SDS-MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Oct.-11-2018Print Date:Oct.-11-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :CID 16020046Catalog No. :HY-16697CAS No. :834903-43-41.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:CID16020046;CID-16020046Formula:C25H19N3O4Molecular Weight:425.44CAS No. :834903-43-44. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

高效液相色谱-串联质谱法测定10_种蔬菜基质中40_种农药的基质效应研究

第52卷第10期辽宁化工 Vol.52，No.10 2023年10月 Liaoning Chemical Industry October，2023收稿日期： 2022-10-20 高效液相色谱-串联质谱法测定10种蔬菜基质中40种农药的基质效应研究罗景阳（沈阳市食品药品检验所，辽宁沈阳110124)）摘要：使用高效液相色谱-串联质谱法（HPLC-MS/MS）测定了40种农药在10种蔬菜基质中产生的基质效应（ME）。

结果表明：QuEChERS净化后的基质标样优于未净化的基质标样；大多数农药在不同基质中表现出弱基质效应和中基质效应，基质效应范围为0.2~1.94，且多数农药在基质中表现为基质抑制，只有黄瓜和茄子表现为基质增强；通过对不同蔬菜中基质效应离散程度研究发现，油麦菜、茄子、架豆王、姜超出合理离散范围，其他6种基质效应一致性较高，可用作基质匹配标曲来降低基质效应影响。

关键词：农药；基质效应；高效液相色谱-串联质谱法；蔬菜中图分类号：O657.63 文献标识码： A 文章编号： 1004-0935（2023）10-1545-05近年来，随着科技工业的不断发展，农药被大量使用，导致农产品中农药残留超标的情况时有发生，对人类的生命安全造成危害[1]。

目前，已经有许多国家和地方标准可以有效地进行农药残留量的检测，但是农产品种类繁多，基质成分复杂，对检测农药残留的准确性造成严重影响。

基质效应（ME）是指样品中除了被检测化合物以外的物质使检测结果增强或减弱，从而影响结果准确性的现象[2-3]。

随着质谱检测技术不断更新，基质效应带来的影响也越来越引起人们的关注，基质效应产生的原因复杂多样，包括被分析物的结构和性质、样品的种类、性状、所含成分以及仪器的条件等[4]，但是目前基质效应产生的机理尚不完全明确，还不能从根本上消除[5]，所以，有效地减少基质效应带来的影响成为准确进行农残检测工作的前提。

顶空气相色谱法测定羧甲基壳聚糖中氯乙酸残留量

顶空气相色谱法测定羧甲基壳聚糖中氯乙酸残留量刘敬兰;陈连文;何书美【期刊名称】《理化检验-化学分册》【年(卷),期】2012(048)002【摘要】采用顶空气相色谱法间接测定了羧甲基壳聚糖中氯乙酸的残留量。

样品（0．2g）于顶空瓶中超声溶解在水3mL中，加入甲醇2．5mL，硫酸1．5mL，在70℃水浴反应40min使之酯化。

按顸空条件进样，用HP-INNOWAX毛细管色谱柱分离，氢火焰离子化检测器测定。

分别选择15min和85℃作为样品在顶空瓶中的平衡时间和平衡温度。

氯乙酸的质量在0．2-20mg范围内与其峰面积呈线性关系，方法的检出限（3S／N）为5．6mg·L^-1。

方法用于实样中氯乙酸的测定，用标准加入法做回收试验，测得回收率在90．0％-92．09／6之间，测定值的相对标准偏差（n=5）在0．7％-0．9％之间。

【总页数】4页(P144-146,149)【作者】刘敬兰;陈连文;何书美【作者单位】河北师范大学实验中心,石家庄050016;河北经贸大学生物科学与工程学院,石家庄050061;河北师范大学实验中心,石家庄050016【正文语种】中文【中图分类】O657.7【相关文献】1.顶空气相色谱法测定甜菜碱中的一氯乙酸(盐)和二氯乙酸(盐) [J], 何沁桂;姚晨之;严方2.自动顶空气相色谱法测定肌氨肽苷注射液中三氯乙酸残留量 [J], 张丽芳; 张冬梅; 朱红志; 秦旭荣3.柱前衍生化高效液相色谱法测定他达拉非中氯乙酸残留量 [J], 徐然4.顶空气相色谱法测定罗氟司特中起始原料溴甲基环丙烷的残留量 [J], 张云;于梦;付丙月;段崇刚;孙玲5.高效液相色谱法测定羧甲淀粉钠(浆状)中氯乙酸残留量 [J], 聂雪玫;周雪芸;郑霞因版权原因，仅展示原文概要，查看原文内容请购买。

高效液相色谱-质谱联用法分析降糖中药制剂中含有的西药成分

高效液相色谱-质谱联用法分析降糖中药制剂中含有的西药成分束昇阳;陈志远【期刊名称】《中国民族民间医药》【年(卷),期】2010(019)013【摘要】目的:应用高效液相色谱-质谱(LC-MS)技术分析中药降糖制剂中可能存在的西药成分.方法:采用高效液相色谱-质谱法对降糖中药制剂进行全扫描和SIR定量分析,对临床常用降糖药中含有西药成分的进行筛选.色谱柱:Agilent Zorbax SB-C18(150mm×4.6 mm,5 μm);保护柱:Agilent Zorbax SB-C18(12.5 mm×4.6 mm,5 μm);流动相:甲醇-10 mmol·L-1乙酸铵-冰醋酸(70:30:0.02);柱温:3O℃.流速:0.2 mL·min-1.结果:所测定的中药降糖药中含有一种西药组分,为苯乙双胍,峰保留时间在2.6 min,其浓度与峰面积呈良好的线性关系.结论:本方法可用于中药降糖药中西药成分的分析.【总页数】2页(P29-30)【作者】束昇阳;陈志远【作者单位】江苏省中医院,江苏,南京,210029;江苏省中医院,江苏,南京,210029【正文语种】中文【中图分类】R927.2【相关文献】1.超高效液相色谱-质谱/质谱联用法快速测定苦碟子注射液中两种倍半萜内酯类成分的含量＊2.反相高效液相色谱法检测降糖类中药制剂及中药保健品中双胍类及磺酰脲类成分3.液相色谱-质谱联用法检测某些降糖中药制剂中的磺酰脲类化学药4.超高效液相色谱-串联质谱联用法同时检测降糖类和减肥类保健品中20种非法添加的化学降糖药物5.超高效液相色谱-质谱联用法与气相色谱-质谱联用法分析水性印油印记的主要成分因版权原因，仅展示原文概要，查看原文内容请购买。

高效液相色谱-质谱法测定降血压保健食品中的8种违禁添加成分

高效液相色谱-质谱法测定降血压保健食品中的8种违禁添加成分卢亚玲;陈继涛;陈波;姚守拙【期刊名称】《色谱》【年(卷),期】2009(27)1【摘要】建立了降血压保健食品中8种违禁添加成分的高效液相色谱-电喷雾质谱联用(HPLC-ESI/MS)测定方法.采用Spherigel C18反相色谱柱,以0.005 mol/L甲酸铵缓冲盐(pH 3.0)-乙腈-甲醇为流动相,梯度洗脱,质谱定性定量.在该条件下,以西力士为内标,ESI+模式下的最低枪出限(LOD)为2.5μg/L;ESI-模式下的最低检出限为50μg/L;回收率为63.3%～107.4%.该方法的样品处理简单,结果准确,重现性好,选择性及灵敏度高,适用范围广,可用于降压类药物及保健食品中违禁成分的检测.【总页数】6页(P44-49)【作者】卢亚玲;陈继涛;陈波;姚守拙【作者单位】湖南师范大学化学生物学及中药分析省部共建教育部重点实验室,湖南,长沙,410081;湖南师范大学化学生物学及中药分析省部共建教育部重点实验室,湖南,长沙,410081;湖南师范大学化学生物学及中药分析省部共建教育部重点实验室,湖南,长沙,410081;湖南师范大学化学生物学及中药分析省部共建教育部重点实验室,湖南,长沙,410081【正文语种】中文【中图分类】O658【相关文献】1.高效液相色谱-串联质谱法测定减肥保健食品中违禁添加药物利莫那班 [J], 马微;何浩;王海波;王秀君;陈伟;李永亮;唐英章2.高效液相色谱-串联质谱法测定兽药粉剂中18种磺胺类违禁添加药物 [J], 王晓利;郭涛;王珊珊;赵金;苑金鹏;赵汝松3.基质分散固相萃取-高效液相色谱-串联质谱法同时测定减肥保健食品中20种违禁添加药物 [J], 马微;程丽;张兰威;张英春;王海波;焦月华;代汉慧;唐英章4.QuEChERS前处理技术联合液相色谱-四极杆飞行时间质谱法检测保健食品中24种违禁降血糖、降血压和降血脂药物 [J], 丁博;王志元;谢建军;曾广丰;李荀;佘志刚;陈文锐5.高效液相色谱-三重四极杆复合离子阱质谱法快速检测保健食品中30种缓解疲劳、改善睡眠类违禁添加药物 [J], 甘凝岚;孙春华;周玮;刘长宇因版权原因，仅展示原文概要，查看原文内容请购买。

双波长薄层扫描法测定复方布洛芬片中主药的含量

双波长薄层扫描法测定复方布洛芬片中主药的含量
杜迎翔;陈玉英;李康乐;李晓燕
【期刊名称】《中国药科大学学报》
【年(卷),期】1995(26)4
【摘要】建立了复方布洛芬片的双波长薄层扫描测定方法，研究了薄层色谱条件、薄层散射作用及扫描条件对薄层色谱扫描的影响。

采用硅胶ＧＦ＿（２５４）－０．７５％ＣＭＣ－Ｎａ薄层板，以乙酸乙酯－甲醇－氨水（７５：１５：１０）为展开剂，用岛津ＣＳ－９０００型薄层扫描仪，双波长反射法锯齿扫描，以随行外标二点法定量对样品进行了分析，布洛芬和伪麻黄碱的回收率分别为１００．２％和１０１．９％，ＲＳＤ＜３．３％（ｎ＝５），三个批号的复方布洛芬片测定结果与ＨＰＬＣ法比较，两者一致。

【总页数】4页(P209-212)
【关键词】布洛芬;片剂;伪麻黄碱;薄层色谱扫描
【作者】杜迎翔;陈玉英;李康乐;李晓燕
【作者单位】中国药科大学分析化学教研室,中国药科大学分析计算中心
【正文语种】中文
【中图分类】TQ460.72
【相关文献】
1.双波长薄层扫描法测定复方替米沙坦制剂中主药的含量 [J], 陶明涛;于香安
2.双波长薄层扫描法测定复方川贝精片中盐酸麻黄碱的含量 [J], 洪立湘;周春莲;沈
丽娟
3.双波长薄层扫描法测定复方桔梗片中吗啡的含量 [J], 张宗仁;姜玉
4.双波长薄层扫描法测定中药复方软肝片中芍药苷含量的研究 [J], 蔡光明;张新全;张苏刚;韩晋
因版权原因，仅展示原文概要，查看原文内容请购买。

标准药品红外光谱查询系统

标准药品红外光谱查询系统范明;谢狄霖【摘要】介绍了标准药品红外光谱信息查询系统的程序设计和应用方法.系统程序用 Microsoft VB语言编写,在Windows平台上运行.数据库用 Microsoft Access 软件管理.系统数据库包含标准药品红外光谱1100多张,可以分别按药品的中文名称、英文名称、原子数、分子式或光谱编号进行查询,得到试样药品的相关信息及其标准谱图·系统程序还允许用户将本专业一些常用化合物的有关信息及其标准红外光谱图添加进数据库,以供日后查询.【期刊名称】《分析仪器》【年(卷),期】2008(000)004【总页数】4页(P15-18)【关键词】药品;红外光谱;数据库;查询系统【作者】范明;谢狄霖【作者单位】福建省药品检验所,福州,350001;福建省医学科学研究所,福建省医学测试重点实验室,福州,350001【正文语种】中文【中图分类】TP31 系统简介红外光谱常作为“分子指纹”广泛应用于分子结构研究和物质种类的鉴别。

未知物红外光谱与标准红外光谱图之间的峰-峰匹配，即“指纹”核对，通常是鉴别化合物的有效方法[1]。

近年来这一方法已越来越多地应用于药品的检验和质量控制。

目前我国国家药典委员会已正式出版了三册《药品红外光谱集》，收录了1100多张标准药品红外光谱, 并编有《中文名索引》、《英文名索引》、《分子式索引》三种索引工具，供使用者手工检索[2]。

随着今后标准药品红外光谱数量的不断扩充，手工查找书本费时费力的缺点将日益突出。

为此，我们进行了标准药品红外光谱信息管理系统的开发研究。

该系统数据库目前包括国家药典委员会已正式出版的《药品红外光谱集》的标准药品红外光谱1100多张,可以分别按中文名、英文名、原子数、分子式或光谱编号进行查询。

整个系统包括光谱信息查询和数据库增添两大模块，此外还包含光谱信息数据库和光谱图形数据库。

各模块内部又分成子模块结构，以利于系统功能的扩充和维护。

丁香醛检测

丁香醛检测
丁香醛（Syringaldehyde）是一种化学物质，主要来源于肉桂成熟果实，目前已应用于医药、香料、农药化学和有机合成工业等领域。

迪信泰检测平台采用高效液相色谱(HPLC)和生化法，可高效、精准的检测丁香醛的含量变化。

此外，我们还提供其他木质素单体检测服务，以满足您的不同需求。

HPLC测定丁香醛样本要求：
1. 请确保样本量大于0.2g或者0.2mL。

周期：2~3周
项目结束后迪信泰检测平台将会提供详细中英文双语技术报告，报告包括：
1. 实验步骤（中英文）
2. 相关质谱参数（中英文）
3. 质谱图片
4. 原始数据
5. 丁香醛含量信息。